Tarsus issues pre-funded warrants as part of securities purchase agreement

Tarsus Pharmaceuticals, Inc. issued a pre-funded warrant to purchase up to a total of shares of common stock with an exercise price of $0.0001. The warrant is part of a series issued pursuant to a Securities Purchase Agreement dated August 5, 2026.